LABORATORY RESEARCH NOTICE:
This monograph is compiled strictly FOR IN-VITRO LABORATORY RESEARCH USE ONLY. All compounds, pathways, and analytical procedures discussed herein are intended solely for preclinical and in-vitro scientific inquiry. Under no circumstances should this material be used for clinical, diagnostic, or human administration purposes.
1. Introduction & Chemical Profiles
In neuroendocrine research, growth hormone secretagogues (GHS) comprise synthetic peptides engineered to investigate somatotropic signaling. Combining CJC-1295 and Ipamorelin represents the premier experimental standard for examining synergistic, supra-additive growth hormone (GH) release. Rather than activating redundant pathways, these two ligands simultaneously recruit distinct cell-surface receptor families on the anterior pituitary somatotroph:
- CJC-1295 (Modified GRF 1-29): A 29-amino acid synthetic GHRH analog with four amino acid substitutions (
D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷) that resist DPP-IV enzymatic cleavage and oxidation while maintaining high affinity for the GHRH receptor (GHRHR). - Ipamorelin: A synthetic pentapeptide ghrelin mimetic (
Aib-His-D-2Nal-D-Phe-Lys-NH₂) that selectively binds the Growth Hormone Secretagogue Receptor 1a (GHSR-1a) without stimulating corticotropic or lactotropic cascades.
Chemical Identity & Profile Reference
| Parameter | CJC-1295 (No DAC) | CJC-1295 (With DAC) | Ipamorelin |
|---|---|---|---|
| CAS Registry Number | 863288-34-0 | 863288-34-0 (modified) | 170851-70-4 |
| Peptide Classification | GHRH(1-29) Analog | Bioconjugated GHRH Analog | Synthetic Ghrelin Mimetic |
| Molecular Weight | ~3367.97 Da | ~3647.28 Da | 711.85 Da |
| Amino Acid Sequence | [D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]GHRH(1-29)-NH₂ | Mod GRF(1-29) + Lys(MPA) | Aib-His-D-2Nal-D-Phe-Lys-NH₂ |
| In-Vitro Biological Half-Life | ~30 minutes | ~6 to 8 days (in vivo) | ~2 hours |
| Primary Target Receptor | GHRH Receptor (GHRHR) | GHRH Receptor (GHRHR) | GH Secretagogue Receptor (GHSR-1a) |
| Signaling Transduction | Gαs → cAMP → PKA | Gαs → cAMP → PKA | Gαq/11 → PLC → IP₃ / DAG → PKC |
2. Receptor Crosstalk: Dual-Pathway Synergy Mechanics
The molecular rationale for co-administering CJC-1295 and Ipamorelin is the simultaneous recruitment of non-overlapping, complementary intracellular cascades in pituitary somatotrophs.
[ CJC-1295 ] [ Ipamorelin ]
│ │
▼ ▼
GHRHR (Gαs) GHSR-1a (Gαq)
│ │
Adenylyl Cyclase Phospholipase C (PLC)
│ ┌──────┴──────┐
▼ ▼ ▼
cAMP Surge IP3 DAG
│ │ │
▼ ▼ ▼
Protein Kinase A (PKA) ER Ca2+ Release PKC
│ │ │
└─────────────────┬───────────────────┴─────────────┘
▼
[ SUPRA-ADDITIVE GH EXOCYTOSIS ]
Complementary Second-Messenger Cascades
- The GHRHR-Gαs-cAMP-PKA Pathway (CJC-1295): Binding to GHRHR activates adenylyl cyclase, converting ATP to cyclic AMP (cAMP). Elevated cAMP activates Protein Kinase A (PKA), which opens L-type voltage-gated Ca²⁺ channels to promote extracellular calcium influx and phosphorylates CREB to stimulate GH gene transcription.
- The GHSR-1a-Gαq/11-PLC-PKC Pathway (Ipamorelin): GHSR-1a agonism activates Phospholipase C (PLC), hydrolyzing PIP₂ into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers immediate discharge of sequestered endoplasmic reticulum Ca²⁺, while DAG activates Protein Kinase C (PKC) to prime secretory vesicles.
Synergistic Pulse Amplification & Selectivity
When tested alone, GHRH analogs are constrained by endogenous somatostatin tone and extracellular Ca²⁺ transit, while ghrelin mimetics deplete finite intracellular pools. Co-incubation uncouples somatostatinergic suppression and pools dual Ca²⁺ mechanisms, producing a supra-additive secretory pulse far exceeding the sum of either compound alone. Furthermore, unlike GHRP-6 or GHRP-2, Ipamorelin exhibits exceptional somatotropic selectivity, with no statistically significant elevation of ACTH, cortisol, or prolactin.
3. The Pharmacokinetic Pivot: DAC vs. No-DAC
In designing experimental protocols, researchers must evaluate whether to utilize CJC-1295 with or without the Drug Affinity Complex (DAC).
PULSATILE DYNAMICS (No DAC + Ipamorelin) CONTINUOUS BASAL MODEL (With DAC)
GH GH
▲ /\ /\ /\ ▲
│ / \ / \ / \ │ ────────────────────────── (Basal elevated)
└──┴────┴──┴────┴──┴────┴────────► └──┴─────────────────────────►
Time (Hours) Time (Days)
• Mimics endogenous ultradian rhythm • High risk of receptor desensitization
Chemistry of the Drug Affinity Complex
DAC incorporates a maleimidopropionic acid (MPA) reactive group coupled to the C-terminal lysine (Lys³⁰(MPA)). In biological matrices containing albumin, MPA undergoes a spontaneous Michael addition to the free thiol on cysteine-34 (Cys³⁴) of albumin. This bioconjugation extends peptide circulatory half-life from ~30 minutes to 6–8 days.
Mechanistic Comparison for Assay Design
| Experimental Feature | Mod GRF 1-29 (No DAC) | CJC-1295 with DAC |
|---|---|---|
| Elimination Half-Life | ~30 minutes | ~6 to 8 days |
| Release Kinetics | Discrete, physiological pulse | Continuous, elevated baseline |
| Receptor Dynamics | Preserves GHRHR recycling | Continuous occupancy; tachyphylaxis risk |
| Stack Compatibility | Optimal with Ipamorelin (~2 hr half-life) | Unsuitable for discrete pulse assays |
| Primary Research Scope | Physiological pulse & circadian models | Chronic baseline & IGF-1 elevation |
For investigating physiological secretagogue synergy, CJC-1295 without DAC is the scientifically indicated pairing with Ipamorelin, synchronizing receptor kinetics into an acute, physiological exocytic surge.
4. Reconstitution & Concentration Protocol
Accurate handling of lyophilized cakes maintains secondary structure and ensures reproducible analytical results.
Diluent Selection & Laboratory Technique
- Bacteriostatic Water (0.9% Benzyl Alcohol): Suitable for multi-entry research vials stored over 21–28 days.
- Sterile 0.9% Sodium Chloride: Preferred for in-vitro cell cultures sensitive to benzyl alcohol cytotoxicity.
- Dissolution Technique: Warm vials to 20°C–25°C. Direct diluent down the interior glass wall—never directly onto the lyophilized powder. Swirl gently; never vortex or agitate mechanically.
Laboratory Dilution Reference Table
| Peptide Compound | Vial Mass | Diluent Volume | Final Concentration | Volume per 100 mcg Dose |
|---|---|---|---|---|
| CJC-1295 (no DAC) | 2.0 mg | 1.0 mL | 2.0 mg/mL (2,000 mcg/mL) | 0.05 mL (50 µL / 5 IU) |
| CJC-1295 (no DAC) | 2.0 mg | 2.0 mL | 1.0 mg/mL (1,000 mcg/mL) | 0.10 mL (100 µL / 10 IU) |
| Ipamorelin | 2.0 mg | 1.0 mL | 2.0 mg/mL (2,000 mcg/mL) | 0.05 mL (50 µL / 5 IU) |
| Ipamorelin | 5.0 mg | 2.5 mL | 2.0 mg/mL (2,000 mcg/mL) | 0.05 mL (50 µL / 5 IU) |
| Ipamorelin | 5.0 mg | 2.0 mL | 2.5 mg/mL (2,500 mcg/mL) | 0.04 mL (40 µL / 4 IU) |
5. Storage Integrity: Separate Vials vs. Combined Blends
Researchers frequently weigh the merits of separate single-compound vials versus pre-blended lyophilized mixtures:
- Degradation Pathways: CJC-1295 possesses three glutamine residues (
Gln⁸,Gln¹⁶,Gln²⁴) prone to deamidation at neutral pH, while Ipamorelin containsHis²susceptible to oxidation. - Inter-Peptide Stability: Concentrated co-solutions increase aggregation risks. Separate storage preserves structural stability and allows variable molar titration.
| Storage Parameter | Lyophilized Cake | Reconstituted (Separate Vials) | Reconstituted (Pre-Blended Vial) |
|---|---|---|---|
| Storage Temperature | -20°C to -80°C | 2°C to 8°C | 2°C to 8°C |
| Solution Shelf Life | Up to 24 months | 28 to 35 days | 14 to 21 days |
| Light Exposure | Complete darkness | Complete darkness | Complete darkness |
| Stoichiometric Control | Independent flexibility | Variable per assay | Rigid, fixed ratio |
6. In-Vitro Incubation Architecture & Timing
In somatotroph primary cell cultures, extracellular substrate conditions and timing windows govern experimental reproducibility:
- Nutrient Interactions: Elevated free fatty acids (FFA) and D-glucose suppress GHRHR-mediated cAMP generation and heighten somatostatinergic tone. Cultures require serum-free, low-glucose basal media equilibrated for 60 minutes prior to challenge.
- Timing Reference Schedule:
| Phase | Time Point | Protocol Action | Target Analytical Endpoint |
|---|---|---|---|
| Equilibration | -60 to 0 min | Pre-wash with serum-free low-glucose media | Endocrine baseline stabilization |
| Challenge | 0 min | Co-administer CJC-1295 (10–100 nM) + Ipamorelin (10–100 nM) | Dual-receptor activation |
| Peak Secretion | +15 to +30 min | Collect conditioned supernatant | Peak GH pulse amplitude (Cmax) |
| Clearance Decay | +60 to +120 min | Serial sampling & cell lysis | Clearance kinetics and total AUC |
7. Analytical Quality Control & Concluding Guidelines
Standard operating procedures for laboratory secretagogue assays must include:
- Purity Validation: Verify ≥98.0% purity by Reversed-Phase HPLC with absorbance monitoring at 214 nm.
- Identity Verification: Confirm exact mass peaks via MALDI-TOF or ESI-LC-MS (~3367.97 Da for Mod GRF 1-29; 711.85 Da for Ipamorelin).
- Controls: Always run vehicle and single-agent baseline controls alongside the combination to validate statistical synergy.
FINAL LABORATORY NOTICE:
This publication provides scientific reference data strictly FOR IN-VITRO LABORATORY RESEARCH USE ONLY. All protocols, molar concentrations, and preparation steps are restricted to legitimate preclinical and in-vitro research. Not for human or animal in-vivo therapeutic use.